Picture of Antibe Therapeutics logo

ATE Antibe Therapeutics Share Price

0.000.00%
ca flag iconLast trade - 00:00
HealthcareAdventurousMicro CapNeutral

Momentum

Relative Strength (%)
1m-3.32%
3m-6.25%
6m-6.73%
1yr-50.79%
Volume Change (%)
10d/3m-25.45%
Price vs... (%)
52w High-50.77%
50d MA+2.99%
200d MA-9.27%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-30.22%
Return on Equity-47.15%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Mar 202331st Mar 2024
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2023 / 2024

Blurred out image of Antibe Therapeutics EPS forecast chart

Profile Summary

Antibe Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is focused on pain, inflammation, and regenerative medicine. The Company’s products pipeline includes Otenaproxesul, ATB-352, and ATB-340. Otenaproxesul is a novel anti-inflammatory drug that releases hydrogen sulfide and combines hydrogen sulfide with naproxen, non-steroidal, anti-inflammatory drug. ATB-352 is a hydrogen sulfide-releasing derivative of ketoprofen. ATB-340 is a gastrointestinal-safe version of low-dose aspirin for cardiovascular and cancer protection. The Company, through its wholly owned subsidiary, Citagenix Inc. (Citagenix) is a seller of tissue regenerative products servicing the orthopaedic and dental marketplaces. Citagenix’s portfolio consists of branded biologics and medical devices that promote bone regeneration.

Directors

Last Annual
March 31st, 2022
Last Interim
June 30th, 2022
Incorporated
May 5th, 2009
Public Since
June 18th, 2013
No. of Employees
37
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
ca flag iconToronto Stock Exchange
Shares in Issue
52,119,276

ATE Share Price Performance

Upcoming Events for ATE

Antibe Therapeutics Inc Annual Shareholders Meeting

Q2 2023 Antibe Therapeutics Inc Earnings Release

Q3 2023 Antibe Therapeutics Inc Earnings Release

Similar to ATE

Picture of AEterna Zentaris logo

AEterna Zentaris

ca flag iconToronto Stock Exchange

Picture of Appili Therapeutics logo

Appili Therapeutics

ca flag iconToronto Stock Exchange

Picture of Aptose Biosciences logo

Aptose Biosciences

ca flag iconToronto Stock Exchange

Picture of Avicanna logo

Avicanna

ca flag iconToronto Stock Exchange

Picture of BELLUS Health logo

BELLUS Health

ca flag iconToronto Stock Exchange

FAQ

Or unlock with your email

Or unlock with your email